ANB Bank Sells 470 Shares of Thermo Fisher Scientific Inc. $TMO

ANB Bank decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,980 shares of the medical research company’s stock after selling 470 shares during the period. ANB Bank’s holdings in Thermo Fisher Scientific were worth $1,208,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Waratah Capital Advisors Ltd. lifted its holdings in shares of Thermo Fisher Scientific by 153.0% in the second quarter. Waratah Capital Advisors Ltd. now owns 7,266 shares of the medical research company’s stock valued at $2,946,000 after purchasing an additional 4,394 shares in the last quarter. Summitry LLC acquired a new stake in Thermo Fisher Scientific in the 2nd quarter valued at approximately $56,164,000. MTM Investment Management LLC bought a new stake in Thermo Fisher Scientific in the 2nd quarter valued at approximately $73,000. Kingsview Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific by 8.2% during the 2nd quarter. Kingsview Wealth Management LLC now owns 23,295 shares of the medical research company’s stock worth $9,445,000 after acquiring an additional 1,760 shares in the last quarter. Finally, Cornerstone Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 177.4% in the second quarter. Cornerstone Advisors LLC now owns 57,700 shares of the medical research company’s stock valued at $23,395,000 after purchasing an additional 36,900 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 17,104 shares of the business’s stock in a transaction on Friday, October 24th. The shares were sold at an average price of $573.54, for a total value of $9,809,828.16. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at $65,247,057.48. This trade represents a 13.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 52,341 shares of company stock worth $29,204,998 in the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

TMO opened at $579.12 on Friday. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The business has a 50 day moving average of $527.90 and a 200-day moving average of $468.04. The stock has a market cap of $217.58 billion, a price-to-earnings ratio of 33.46, a PEG ratio of 3.27 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the prior year, the business earned $5.28 EPS. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific announced that its board has authorized a share buyback program on Thursday, November 6th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 9.94%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on TMO shares. UBS Group raised their target price on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a research report on Thursday, October 23rd. William Blair initiated coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They issued an “outperform” rating for the company. Robert W. Baird upped their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Raymond James Financial reaffirmed an “outperform” rating and set a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Nineteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $601.65.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.